Class III (Contraindications) for Beta-Blockers
Intravenous beta-blockers are potentially harmful (Class III: Harm) in patients with NSTE-ACS who have risk factors for cardiogenic shock, specifically: age >70 years, heart rate >110 bpm, systolic BP <120 mmHg, and late presentation 1.
Absolute Contraindications (Do Not Initiate)
Beta-blockers should not be administered in the following situations:
Cardiac Conduction Abnormalities
- PR interval >0.24 seconds (marked first-degree AV block)
- Second- or third-degree AV block without a functioning permanent pacemaker 1
Hemodynamic Instability
- Signs of heart failure (rales, S3 gallop) at presentation
- Evidence of low-output state (oliguria)
- Increased risk for cardiogenic shock (see risk factors above)
- Hypotension (systolic BP <90 mmHg)
- Significant sinus bradycardia (heart rate <50 bpm) 2, 3, 4
Respiratory Conditions
- Active bronchospasm
- Active asthma requiring airway support
- Reactive airway disease that is severe 1
Heart Failure Context
- Decompensated heart failure requiring intravenous inotropes or mechanical support 5
- Cardiogenic shock 5
Important Nuances and Common Pitfalls
What is NOT a Contraindication (Contrary to Common Belief)
Stable COPD or history of asthma without active bronchospasm is NOT a contraindication 1. Beta-1 selective agents (metoprolol, bisoprolol) should be initiated at low doses in these patients. The guidelines explicitly state that mild wheezing or COPD history mandates a cardioselective agent at reduced dose rather than complete avoidance 2, 3.
Compensated heart failure with reduced ejection fraction (LVEF <0.40) is actually a strong indication for beta-blockers before discharge, not a contraindication 1. The key distinction is between decompensated (contraindication) versus compensated/stabilized (indication).
Peripheral vascular disease is not an absolute contraindication unless there is active rest ischemia 6.
Route-Specific Considerations
The Class III: Harm designation applies specifically to intravenous beta-blockers in high-risk patients 1. Oral beta-blockers can often be initiated cautiously once hemodynamic stability is achieved, even in patients initially at risk for shock.
Re-evaluation Mandate
Patients with documented contraindications in the first 24 hours should be re-evaluated to determine subsequent eligibility 1. Many initial contraindications (hypotension, tachycardia, volume overload) resolve with appropriate management, allowing safe beta-blocker initiation before discharge.
Critical Risk Stratification for Shock
The COMMIT trial identified patients at highest risk for cardiogenic shock from IV beta-blockers: those with tachycardia OR Killip Class II or III 3, 4. This represents a specific, evidence-based population where IV administration causes harm.